Advances in Targeted Photodynamic Therapy Based on Nanotechnology
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 20 August 2024 | Viewed by 751
Special Issue Editors
Interests: photodynamic therapy; controlled drug release; nanobiophotonics; light-matter interaction; nonlinear optics
Interests: photodynamic therapy; anticancer metallodrugs; nanocarriers; targeted drug delivery; biomolecular drug targets
Special Issue Information
Dear Colleagues,
Photodynamic therapy (PDT) is a noncumulative, noninvasive, and selective therapeutic modality exploited in treating various types of cancer, infections, inflammation, or wound healing. PDT relays on either focal or systemic application of photosensitizers (PSs) accumulated in pathological tissues and illumination in the form of X-rays, ultraviolet, visible, or infrared light. PS molecules absorb the irradiation of the appropriate wavelength, initiating a series of reactions leading to the selective destruction of the pathological cells by reactive oxygen species-mediated killing, blood vessel damage, and activation of the immune response. However, broad clinical applications of PDT are still hindered due to low cell/tissue selectivity and meager water solubility of PSs, limited light penetration depth, effortless recognition by the immune system, swift clearance from blood circulation, and other factors.
The seemingly unstoppable development of nanotechnology led to unparalleled, innovative, nanoparticle-based solutions that profoundly improve targeting and camouflage capability, solubility, biocompatibility, penetrability, light conversion efficiency, and PS circulation time. Original research articles, brief reports, and communications offering novel ideas and nano tricks on bypassing biological barriers, reducing dosage and side effects, improving real-time monitoring of drug release and distribution, and maximizing PDT efficiency are welcomed. In addition, opinions and reviews dealing with nanotechnology-driven progress in targeted PDT are also eligible for submission to this Special Issue which hopefully will contribute to global efforts towards the inauguration of fully personalized therapies.
We look forward to receiving your exciting and inspiring contributions.
Dr. Milutin Stepić
Dr. Maja D. Nešić
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- photodynamic therapy
- targeted delivery
- nanoparticles
- controlled release
- nanotheranostics
- photosensitizers
- PDT light sources
